Opinion|Videos|January 31, 2025
ASH 2024 CAR T and Bispecifics Updates: Key Insights and Practical Considerations in 3L R/R FL Treatment
Panelists discuss key highlights from American Society of Hematology (ASH) 2024 updates on long-term follow-ups across chimeric antigen receptor (CAR) T trials and a matching-adjusted indirect comparison (MAIC) of outcomes with liso-cel, axi-cel, and tisa-cel, sharing their impressions of the MAIC data and their influence on day-to-day decision-making.
Advertisement
Episodes in this series
Video content above is prompted by the following:
There have been several ASH 2024 updates, including the longer-term follow-ups across the CAR T trials as well as a MAIC of outcomes with liso-cel vs axi-cel vs tisa-cel. Dr Strati, could you review key highlights of these updates and your impressions of the MAIC data? Do MAIC data influence your day-to-day decision-marking?
Advertisement
Related to this article
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma
3
European Commission Approves Camizestrant Plus CDK4/6 Inhibition for Emergent ESR1-Mutated Advanced Breast Cancer
4
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
5